Michele Stone, PhD

Vice President, Translational Development

Michele Stone is the Vice President of Translational Development at Kriya Therapeutics. Previously, Dr. Stone was the Vice President of Early Development and Head of Nonclinical and Bioanalytical at Axovant Gene Therapies (now Sio Gene Therapies). Prior to this, Dr. Stone was Executive Director of Vaccine Development and Bioanalytical at Liquidia Technologies. Dr. Stone was also the Director of R&D at Aeras where she was responsible for developing and leading partnerships to advance multiple vaccine platforms (viral vector, protein, and nucleic acid) into and through clinical development. She was previously a Senior Scientist at Canon US Life Sciences where she contributed to the development of diagnostics aimed at personalized medicine.

Dr. Stone received her PhD in Biochemistry and Molecular Biology from the University of Maryland, where she also completed her postdoctoral fellowship in Physiology and Neuroscience. She received her undergraduate degree in Chemistry from Lynchburg College.